PCS与PAM50前列腺癌分类方案的比较研究
该研究比较了基于转录组的前列腺癌分类系统PCS与PAM50变体,将9947例前列腺癌患者分为PCS和PAM50亚型。两种分类系统在分子谱和临床结局上相似,但PCS在细胞过程分离及管腔/基底标记表达上更优,且风险比更大,亚型间结局区分更清晰。
要点
- PCS与PAM50亚型在基因表达、细胞过程和临床结局上存在一定一致性。
- PCS系统对管腔和基底特征及细胞过程的分离优于PAM50。
- PCS系统基于更大的风险比,对侵袭性亚型的临床结局区分更清晰。
核心结论
- PCS与PAM50分类系统在分子谱和临床结局上相似,但PCS在多个临床结局上分离更明显,且能更好区分前列腺管腔和基底特征。
研究设计与样本
- 研究比较了PCS(37基因)和PAM50(50基因)分类系统,将9947例前列腺癌患者分为PCS和PAM50亚型。
- 评估了 hallmark 基因集富集、管腔和基底标记基因表达,并进行了生存分析。
主要发现
- PCS和PAM50亚型显示PCS37和PAM50基因的差异表达,两系统仅共享三个基因。
- 三对亚型(PCS1 vs Luminal B、PCS2 vs Luminal A、PCS3 vs Basal)在基因表达、细胞过程和临床结局上存在一定共识。
- PCS分类在细胞过程及管腔/基底标记基因表达上比PAM50分离更好。
- PCS1和Luminal B肿瘤均显示最差的临床结局,但PCS系统中侵袭性与非侵袭性亚型间的结局区分更明确,基于更大的风险比。
临床怎么用
- PCS分类系统可能提供更好的前列腺癌分子亚型区分,有助于临床结局评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two prostate cancer (PC) classification methods based on transcriptome profiles, a de novo method referred to as the "Prostate Cancer Classification System" (PCS) and a variation of the established PAM50 breast cancer algorithm, were recently proposed. Both studies concluded that most human PC can be assigned to one of three tumor subtypes, two categorized as luminal and one as basal, suggesting the two methods reflect consistency in underlying biology. Despite the similarity, differences and commonalities between the two classification methods have not yet been reported. METHODS: Here, we describe a comparison of the PCS and PAM50 classification systems. PCS and PAM50 signatures consisting of 37 (PCS37) and 50 genes, respectively, were used to categorize 9,947 PC patients into PCS and PAM50 classes. Enrichment of hallmark gene sets and luminal and basal marker gene expression were assessed in the same datasets. Finally, survival analysis was performed to compare PCS and PAM50 subtypes in terms of clinical outcomes. RESULTS: PCS and PAM50 subtypes show clear differential expression of PCS37 and PAM50 genes. While only three genes are shared in common between the two systems, there is some consensus between three subtype pairs (PCS1 versus Luminal B, PCS2 versus Luminal A, and PCS3 versus Basal) with respect to gene expression, cellular processes, and clinical outcomes. PCS categories displayed better separation of cellular processes and luminal and basal marker gene expression compared to PAM50. Although both PCS1 and Luminal B tumors exhibited the worst clinical outcomes, outcomes between aggressive and less aggressive subtypes were better defined in the PCS system, based on larger hazard ratios observed. CONCLUSION: The PCS and PAM50 classification systems are similar in terms of molecular profiles and clinical outcomes. However, the PCS system exhibits greater separation in multiple clinical outcomes and provides better separation of prostate luminal and basal characteristics.
引用
- Yoon J, Kim M, Posadas EM, et al. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis. 2021. PMID: 33531653. doi:10.1038/s41391-021-00325-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。